Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>

US FDA Grants Orphan Drug Status to CSPC Pharmaceutical's Gastric Cancer Injection

MT Newswires ·  {{timeTz}}

02:00 AM EDT, 07/29/2022 (MT Newswires) -- The US Food and Drug Administration granted orphan drug status to CSPC Pharmaceutical Group's (HKG:1093) docetaxel for injection for the treatment of gastric cancer, including gastroesophageal junction cancer.

The injectable uses a human serum albumin encapsulation technology to deliver docetaxel in nanoparticles in patients, which will remove the need for premedication with hormones, according to a Thursday stock filing.

Shares dropped nearly 2% in Friday afternoon trading.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top